Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Brian, Hee"'
Publikováno v:
Clinical Pharmacology in Drug Development
Glasdegib is a potent, selective oral inhibitor of the Hedgehog signaling pathway. This phase 1 double‐blind thorough QT study (NCT03162900) evaluated the effects of glasdegib on QTc interval. The study enrolled 36 healthy volunteers to receive a s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe5a851864f768627bb3d6e3838618b4
https://doi.org/10.1002/cpdd.862
https://doi.org/10.1002/cpdd.862
Publikováno v:
Clinical Pharmacology in Drug Development
Glasdegib (PF‐04449913) is an oral small‐molecule inhibitor of the Hedgehog signaling pathway under development for treating myeloid malignancies. This was an open‐label phase 1, randomized, 2‐sequence, 2‐treatment, 2‐period, crossover st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1318e6fffe48483fb617ed2c4bb88312
http://europepmc.org/articles/PMC6850403
http://europepmc.org/articles/PMC6850403
Publikováno v:
Journal of Pharmacokinetics and Pharmacodynamics
This population pharmacokinetics analysis evaluated the target-mediated drug disposition of inotuzumab ozogamicin (InO) through an empirical time-dependent clearance (CLt) term and identified potential covariates that may be important predictors of v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c42e51a40ed025dfbdde343a1d49bb8
https://doi.org/10.1007/s10928-018-9614-9
https://doi.org/10.1007/s10928-018-9614-9
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose To demonstrate the bioequivalence of the planned maleate salt-based commercial glasdegib tablet formulation [International Council for Harmonization (ICH) glasdegib] to the clinical di-hydrochloride (di-HCl) salt-based glasdegib formulation (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98866f60ce04c16c7cd0c5e2df9d182b
https://doi.org/10.1007/s00280-018-3748-8
https://doi.org/10.1007/s00280-018-3748-8
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Glasdegib is being developed for indications in myeloid malignancies. The effect of renal impairment on the pharmacokinetics (PK) of a single, oral, 100-mg glasdegib dose under fasted conditions was assessed. Methods Open-label, parallel-grou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94b02bcf33d5a7da336335de6ecb7311
https://pubmed.ncbi.nlm.nih.gov/33388951
https://pubmed.ncbi.nlm.nih.gov/33388951
Publikováno v:
British Journal of Clinical Pharmacology. 84:1346-1353
SummaryAIMS This study aimed to evaluate the effect of a strong CYP3A inducer, rifampin, on glasdegib pharmacokinetics in healthy volunteers. METHODS In an open-label, fixed-sequence, two-period Phase 1 study, subjects received a single 100-mg oral d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f2caed97b7cbdcbefe1cdad9aa3c5fbc
https://doi.org/10.1111/bcp.13568
https://doi.org/10.1111/bcp.13568
Publikováno v:
Xenobiotica. 47:1064-1076
1. The metabolism, excretion and pharmacokinetics of glasdegib (PF-04449913) were investigated following administration of a single oral dose of 100 mg/100 μCi [14C]glasdegib to six healthy male volunteers (NCT02110342). 2. The peak concentrations o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::82f337b75660c6961451a1e6d290fb1a
https://doi.org/10.1080/00498254.2016.1261307
https://doi.org/10.1080/00498254.2016.1261307
Publikováno v:
British journal of clinical pharmacology. 84(6)
AIMS: This study aimed to evaluate the effect of a strong CYP3A inducer, rifampin, on glasdegib pharmacokinetics in healthy volunteers. METHODS: In an open‐label, fixed‐sequence, two‐period Phase 1 study, subjects received a single 100‐mg ora
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0a4bf103a818b6e48c1f9894c92a8e2d
https://pubmed.ncbi.nlm.nih.gov/29488303
https://pubmed.ncbi.nlm.nih.gov/29488303
Autor:
Nagdeep Giri, Brian Hee, Naveed Shaik, Robert R. LaBadie, Yali Liang, Joseph F. Krzyzaniak, Lisa H. Lam, Hong Jiang
Publikováno v:
Cancer chemotherapy and pharmacology. 80(6)
This phase I open-label study investigated the oral bioavailability of two novel maleate salt-based glasdegib (PF-04449913) tablet formulations (small- and large-particle size) relative to the current clinical formulation (diHCl salt-based). In addit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce734d201cbbd99ec020e57781ddcab4
https://pubmed.ncbi.nlm.nih.gov/29086063
https://pubmed.ncbi.nlm.nih.gov/29086063
Publikováno v:
British Journal of Clinical Pharmacology. 77:480-492
AIMS Axitinib is a potent and selective second generation inhibitor of vascular endothelial growth factor receptors 1, 2 and 3 approved for second line treatment of advanced renal cell carcinoma. The objectives of this analysis were to assess plasma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::67be768a53f6c47eb078b3baf3ecbb1d
https://doi.org/10.1111/bcp.12206
https://doi.org/10.1111/bcp.12206